Intended for healthcare professionals

News

Semaglutide reduces risk of major cardiovascular events by 20%, finds study

BMJ 2023; 383 doi: https://doi.org/10.1136/bmj.p2668 (Published 13 November 2023) Cite this as: BMJ 2023;383:p2668
  1. Jacqui Wise
  1. Kent

A weekly injection of semaglutide (Wegovy) resulted in a 20% reduction in the risk of death from major cardiovascular events in people classed as overweight or obese who were not diabetic, according to trial results published in the New England Journal of Medicine.1

The headline results from the Select trial were previously reported by the manufacturer Novo Nordisk in August.

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist and is used to treat type 2 diabetes under its brand name Ozempic. In March, the National Institute for Health and Care Excellence recommended semaglutide can be prescribed to help people lose weight as part of their treatment in a NHS specialist weight management service. …

View Full Text

Log in

Log in through your institution

Subscribe

* For online subscription